ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.
Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.
Siehe auch...
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | ¥203.00 ¥372.00 ¥982.00 ¥1895.00 ¥2854.00 ¥5596.00 ¥10267.00 | 5 | |
ROCK-Inhibitor, der die ARHGAP-Aktivität durch eine verringerte Rückkopplung des Weges stabilisieren kann. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | ¥1173.00 ¥4107.00 | 7 | |
Ein weiterer Rho-Kinase-Inhibitor, der möglicherweise die regulierende Wirkung von ARHGAP39 auf Rho-GTPasen beeinflussen könnte. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | ¥2403.00 ¥10030.00 | 12 | |
Rac1-Inhibitor, der die ARHGAP-vermittelte Signalübertragung durch Stabilisierung von inaktivem Rac1 reduzieren könnte. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | ¥3430.00 ¥6262.00 | ||
Hemmt Trio, einen GEF, der möglicherweise die ARHGAP-vermittelte GTPase-Aktivität verändert. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | ¥6262.00 | ||
Hemmt selektiv die Bindung von RhoA an GEF und moduliert möglicherweise die regulatorischen Wirkungen von ARHGAP. | ||||||
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor Inhibitor | 509093-47-4 | sc-204013 | 5 mg | ¥1839.00 | 2 | |
Cdc42-aktivitätsspezifischer Inhibitor, könnte die regulatorische Wirkung von ARHGAP anpassen. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | ¥1297.00 | ||
Cdc42-Inhibitor, der die von ARHGAP regulierten nachgeschalteten Prozesse beeinflussen könnte. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | ¥1489.00 ¥6047.00 | 1 | |
Hemmt Cytohesine und beeinflusst möglicherweise indirekt die ARHGAP-Aktivität. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | ¥3723.00 | ||
Hemmt die Interaktion zwischen JMY und RhoA und beeinflusst damit indirekt die Aktivität von ARHGAP innerhalb des Rho-GTPase-Wegs. | ||||||